Drug Profile
Research programme: IPL5 series - Aventis/Inflazyme
Alternative Names: IPL5 series research programme - Aventis/Inflazyme; LSAIDs research programme - Aventis/Inflazyme; Research programme: LSAIDs - Aventis/InflazymeLatest Information Update: 15 Feb 2005
Price :
$50
*
At a glance
- Originator Inflazyme Pharmaceuticals
- Class
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 15 Feb 2005 Inflazyme Pharmaceuticals is winding down its LSAIDs™ collaboration with sanofi-aventis
- 30 Jul 2004 No development reported - Preclinical for Inflammation in Canada (unspecified route)
- 24 Feb 2000 IPL 576 compounds are being investigated for potential in atopic dermatitis and allergic conjunctivitis